<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881322</url>
  </required_header>
  <id_info>
    <org_study_id>GAN-2008</org_study_id>
    <nct_id>NCT00881322</nct_id>
  </id_info>
  <brief_title>A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Effects of Gas Defense On Intestinal Gas Symptoms in Otherwise Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miami Research Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ganeden Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Miami Research Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial to determine the safety and
      efficacy of Digestive Advantageâ„¢ Gas Defense formula, a probiotic dietary supplement. The
      study will last approximately four weeks, and subjects will be seen at a
      screening/randomization visit, and two follow-up visits.

      Study procedures will include administering questionnaires for assessment of the study
      product's effect on intestinal gas symptoms and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of daily supplementation with GD as compared to placebo on intestinal gas symptoms as measured by the subscores of the GI Symptom Rating Scale (GSRS) and the subscores of the Severity of Dyspepsia Assessment (SODA).</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Objective To determine if daily supplementation with GD is safe within the confines of this study as denoted by changes from baseline in blood pressure, heart rate, adverse events, and subjective remarks.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Abdominal Pain</condition>
  <condition>Abdominal Cramps</condition>
  <condition>Flatulence</condition>
  <arm_group>
    <arm_group_label>BC-130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BC-130 (Gas Defense)</intervention_name>
    <description>Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.</description>
    <arm_group_label>BC-130</arm_group_label>
    <other_name>Gas Defense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&amp;C yellow #5 Lake, FD&amp;C blue #1 Lake, FD&amp;C red #46 Lake and vegetable capsule</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18-75 years of age.

          -  Subject self-reports at least one of the following symptoms after eating a meal or
             snack:

          -  Abdominal pain/cramps

          -  Distended feeling/bloating

          -  Flatulence/gas

          -  Subject is in otherwise general good health as determined by physical exam and medical
             history.

          -  Subject is willing and able to comply with the protocol.

          -  Female subjects not defined as post-menopausal (excluding hysterectomized and post
             bilateral tubal ligations) must use a reliable method of birth control as defined
             within this protocol.

          -  Subject is able to understand and sign the informed consent (English or Spanish) to
             participate in the study.

        Exclusion Criteria:

          -  Subject has any of the following medical conditions:

               -  active heart disease

               -  renal or hepatic impairment/disease

               -  Type I or II diabetes

               -  psychiatric disorders (hospitalized within the past one year)

               -  bipolar disorder

               -  Parkinson's disease

               -  unstable thyroid disease

               -  immune disorder (such as HIV/AIDS)

               -  any medical condition deemed exclusionary by the Principal Investigator (PI)

          -  Subject has a history of cancer (except localized skin cancer without metastases or in
             situ cervical cancer) within five years prior to screening.

          -  Subject has had any stomach or intestinal surgery (i.e. gastric bypass).

          -  Subject is currently taking antibiotics (or any drug that significantly interferes
             with bacterial flora) or has taken antibiotics within the 30 days prior to
             screening/enrollment.

          -  Subject is currently taking or has used in the past 30 days probiotics or prebiotics.

          -  Subject is on an unstable dose of medication (defined as fewer than 90 days at the
             same dose).

          -  Subject is currently taking any medication deemed exclusionary by PI.

          -  Subject has a history of or currently has any gastrointestinal disorders or
             inflammatory bowel conditions such as Crohn's disease, short bowel, or ulcerative
             colitis. Subjects may not have a diagnosis, be seeing a doctor, or taking prescription
             medication(s) for Irritable Bowel Syndrome (IBS).

          -  Subject has constipation defined as less than three spontaneous bowel movements per
             week.

          -  Subject is lactose intolerant (self-professed or diagnosed).

          -  Subject uses any of the following classification of GI medications two or more times
             per week: anti-spasmodics, motility agents, pro-kinetic agents or laxatives.

          -  Subject plans to use another over-the-counter gas-relief product daily during the
             study period. Over-the-counter gas relief products may be used as rescue medication
             (their use will be captured by the study staff). If a subject is using a fiber
             supplement prior to starting the study, he/she may continue as long as the frequency
             and quantity remain stable throughout the study period.

          -  Subject has an allergy to wheat or fish or any of the other product ingredients (see
             section 2.5.4).

          -  Subject has two or more food allergies.

          -  Subject has a history of drug or alcohol abuse within the past 12 months.

          -  Subject is deemed by the Investigator as an unsuitable candidate for receipt of an
             investigational dietary supplement, or unable to be followed up throughout the entire
             duration of the study.

          -  Female subject of childbearing potential is unwilling to use an acceptable form of
             contraceptive device throughout the study period.

          -  Subject is pregnant, lactating, or planning to become pregnant during the study
             period.

          -  Subject is participating in another clinical trial or has received an investigational
             product within 30 days prior to screening/enrollment.

          -  Subject is deemed by the Investigator as an unsuitable candidate for receipt of an
             investigational dietary supplement, or unable to be followed up throughout the entire
             duration of the study.

          -  Subject is unable to comprehend the Informed Consent and research purpose.

          -  Subject is unable or unwilling to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Krieger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latin American Research</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>September 29, 2009</last_update_submitted>
  <last_update_submitted_qc>September 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Diane Krieger, MD - Principal Investigator</name_title>
    <organization>Miami Research Associates</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
    <mesh_term>Flatulence</mesh_term>
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

